Main Article Content
Abstract
The use of central catheters has increased signifi cantly despite their greater morbi-mortality compared to AVF. The main complications are thrombosis, bacteriaemiasepsis, and limitation of dialysis effi cacy, reducing quality of life for patients and increasing the healthcare cost. In our unit, 5% heparin sodium was previously used as lock solution and we currently use TauroLock™-Hep 500®, composed of (cyclo)-taurolidine (biocompatible antimicrobial agent) 4% citrate and heparin 500 UI/ml . Objective: To verify the effi cacy of Taurolock in reducing the incidence of intraluminal colonization and thrombosis compared with 5% heparin sodium. Material and method: We carried out a longitudinal observational cohort study and we analysed intraluminal colonization, thrombosis, biofi lm and use of antibiotherapy. Results: We observed an improvement in catheter permeability, a reduction in the use of urokinase, reduction in unipuncture sessions and in use of antibiotic. Conclusions: Our study shows that using a lock solution that contains taurolidine as an antimicrobial agent for haemodialysis catheters can signifi cantly reduce the incidence of catheter-related sepsis. Taurolidine appears to be effective and safe and does not entail risks or side effects. The addition of 500 iu of heparin to the lock solution together with 4% citrate has reduced thrombotic events by reducing the use of fi brilolytics and elimina ting completely the use of unipuncture, presenting an improvement in dialysis efficacy.
Keywords
Article Details
Author copyright notice
© Authors grant the publisher the non-exclusive licence to publish the work and consent to its use and distribution under the Creative Commons Attribution - NonCommercial 4.0 International (CC BY-NC 4.0) licence. Read the licensing information and the legal text here. This must be expressly stated wherever necessary.